JP5829871B2 - リポソーム薬剤 - Google Patents
リポソーム薬剤 Download PDFInfo
- Publication number
- JP5829871B2 JP5829871B2 JP2011203497A JP2011203497A JP5829871B2 JP 5829871 B2 JP5829871 B2 JP 5829871B2 JP 2011203497 A JP2011203497 A JP 2011203497A JP 2011203497 A JP2011203497 A JP 2011203497A JP 5829871 B2 JP5829871 B2 JP 5829871B2
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- drug
- molecule
- carrier
- salen complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Description
(リポソームの製造)
抗癌剤を内包したリポソームの製造に必要な脂質を、“Prodrugs Formings High Drug loading Mulutifunctional Nanocapsules for Intracellular cancer Drug Delivery ” J Am Chem Soc.132(2010)4259-4265を参照して製造した。
先ず、ポリエチル・グルコール・モノメチル・エステル(5.50g 10mmol)を無水テトラヒドロフラン20mlに溶解した。その得られた溶液を摂氏−20度に冷却した後、ナトリウム水素化物(0.3g 12mmol)を撹拌しながら冷却溶液に添加した。30分後、得られたポリエチレングリコールに、無水テトラヒドロフラン20mlに溶解した塩化スクシニル(1.55g 10mmol)を添加した。
がん細胞であるPOS−1細胞を24穴プレートに1.0×104/wellに適用して培養した。培養24時間後に上記で合成したリポソーム―キャリア(金属サレン錯体化合物)複合体の濃度を換え投与した。24時間後に細胞回収し、細胞生存アッセイ用のMTT試薬を投与し、45分後に0.04mol/HCl/イソプロピルアルコールを400μl加え、96穴プレートへ100μl分注し、570nmの吸光度を測定し、生存細胞率を計算した。その結果、コントロールでは、細胞生存率は100%であっが、リポソーム―キャリア化合物の複合体の濃度(10μM)程度から癌細胞殺傷効果が増大し、抗癌作用が認められることがわかった。
Claims (1)
- 薬物を内包するリポソームと、
前記リポソームの表面の親水性部分と結合した親水基と、金属サレン錯体と、前記親水基と前記金属サレン錯体とを、アミド結合、エステル結合、又は、ジスルフィド結合を結合させる結合分子と、からなる金属サレン誘導体と、
からなる医薬分子を有効成分として含有するリポソーム薬剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011203497A JP5829871B2 (ja) | 2011-09-16 | 2011-09-16 | リポソーム薬剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011203497A JP5829871B2 (ja) | 2011-09-16 | 2011-09-16 | リポソーム薬剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013063926A JP2013063926A (ja) | 2013-04-11 |
JP5829871B2 true JP5829871B2 (ja) | 2015-12-09 |
Family
ID=48187796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011203497A Active JP5829871B2 (ja) | 2011-09-16 | 2011-09-16 | リポソーム薬剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5829871B2 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6472608B2 (ja) | 2014-05-21 | 2019-02-20 | ソマール株式会社 | N−アセチルグルコサミン糖鎖基含有化合物、薬剤輸送用キャリアー化合物、製剤、及び、薬剤輸送システム |
JP6948660B2 (ja) | 2014-11-13 | 2021-10-13 | 東亞合成株式会社 | 外来物質の細胞内への導入方法ならびに該方法に用いる材料 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090169484A1 (en) * | 2007-12-28 | 2009-07-02 | Ihi Corporation | Iron-salen complex |
JP2009274962A (ja) * | 2008-05-12 | 2009-11-26 | Yoshihiro Ishikawa | 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置 |
KR101050273B1 (ko) * | 2008-11-21 | 2011-07-19 | 세종대학교산학협력단 | 살렌 전이금속 착화합물, 및 그 제조 방법 |
-
2011
- 2011-09-16 JP JP2011203497A patent/JP5829871B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013063926A (ja) | 2013-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Formulation of metal–organic framework-based drug carriers by controlled coordination of methoxy PEG phosphate: boosting colloidal stability and redispersibility | |
Graczyk et al. | Gold nanoparticles in conjunction with nucleic acids as a modern molecular system for cellular delivery | |
Pranantyo et al. | Antimicrobial peptide-reduced gold nanoclusters with charge-reversal moieties for bacterial targeting and imaging | |
Wang et al. | Facile synthesis of uniform virus-like mesoporous silica nanoparticles for enhanced cellular internalization | |
Pramanik et al. | Affimer tagged cubosomes: Targeting of carcinoembryonic antigen expressing colorectal cancer cells using in vitro and in vivo models | |
Nasrolahi Shirazi et al. | Cyclic peptide–selenium nanoparticles as drug transporters | |
Nowinski et al. | Biologically inspired stealth peptide-capped gold nanoparticles | |
Ojea-Jiménez et al. | Facile preparation of cationic gold nanoparticle-bioconjugates for cell penetration and nuclear targeting | |
Kulkarni et al. | Hypoxia responsive, tumor penetrating lipid nanoparticles for delivery of chemotherapeutics to pancreatic cancer cell spheroids | |
Suma et al. | Modulated fragmentation of proapoptotic peptide nanoparticles regulates cytotoxicity | |
Gisbert-Garzaran et al. | Designing mesoporous silica nanoparticles to overcome biological barriers by incorporating targeting and endosomal escape | |
Chen et al. | Subcellular fate of a fluorescent cholesterol-poly (ethylene glycol) conjugate: An excellent plasma membrane imaging reagent | |
Müller-Schiffmann et al. | Hybrid compounds: from simple combinations to nanomachines | |
Peng et al. | DNA nanostructure-programmed cell entry via corner angle-mediated molecular interaction with membrane receptors | |
Ye et al. | High-yield synthesis of monomeric LMWP (CPP)-siRNA covalent conjugate for effective cytosolic delivery of siRNA | |
Fan et al. | Sequence-dependent peptide surface functionalization of metal–organic frameworks | |
EP2175887A1 (en) | Compositions for delivery of therapeutics and other materials | |
Bian et al. | Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery | |
Ding et al. | Improving tumor accumulation of aptamers by prolonged blood circulation | |
Durymanov et al. | Cellular uptake, intracellular trafficking, and stability of biocompatible metal-organic framework (MOF) particles in Kupffer cells | |
KR101580251B1 (ko) | Tpp-pcl-tpp 고분자 및 상기 고분자를 이용한 미토콘드리아 표적 나노약물전달용 조성물 | |
Fei et al. | Hierarchical integration of degradable mesoporous silica nanoreservoirs and supramolecular dendrimer complex as a general-purpose tumor-targeted biomimetic nanoplatform for gene/small-molecule anticancer drug co-delivery | |
Biswas et al. | Anchoring drugs to a zinc (II) coordination polymer network: exploiting structural rationale toward the design of metallogels for drug-delivery applications | |
Zhang et al. | Lipo-oligomer nanoformulations for targeted intracellular protein delivery | |
Fang et al. | Sgc8 aptamer targeted glutathione-responsive nanoassemblies containing Ara-C prodrug for the treatment of acute lymphoblastic leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140421 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150113 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150728 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150828 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150929 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151023 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5829871 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |